Heart failure & cardiomyopathies
Randomized Trial of Cholesterol Lowering With Evolocumab for Cardiac Allograft Vasculopathy in Heart Transplant Recipients
Primary result · Maximal intimal thicknessResult — go to the resultAdjusted mean difference 0.017 mm 95% CI −0.006 to 0.040Authors' conclusion
Twelve months of treatment with evolocumab substantially reduced low-density lipoprotein cholesterol but did not reduce maximal coronary intimal thickness in HTx recipients.
Study context
- Population
- Heart transplant recipients 4 to 8 weeks after transplantation at Nordic transplant centres56 vs 54 with matched IVUS pairs
- Participants
- 128 recipients
- Comparison
- Evolocumab vs placebo
- Primary endpoint
- Baseline-adjusted maximal intimal thickness by intracoronary ultrasound
- Follow-up
- 12 months
Methodological detailsdouble-blind, placebo-controlled, multicentre (Nordic transplant centres), Enrolled June 2019 to May 2022
- Double-blind
- Placebo-controlled
- Multicentre (Nordic transplant centres)
- Enrolled June 2019 to May 2022
Primary result
Maximal intimal thickness
Adjusted mean difference
0.017 mm
95% CI −0.006 to 0.040
P = 0.14
Evolocumab vs Placebo
adjusted mean difference 0.017 mm (95% CI −0.006 to 0.040); P = 0.14
As reported in the abstract
Further findings
| Outcome | Mean reduction (mmol/L) (95% CI) |
|---|---|
| LDL-C reduction | 1.11 (0.86–1.37) |
Safety
- Evolocumab not associated with an increase in adverse events
Original publication
Randomized Trial of Cholesterol Lowering With Evolocumab for Cardiac Allograft Vasculopathy in Heart Transplant Recipients. JACC Heart Fail. Published 26 June 2024. doi:10.
Summarised from the published abstract; every number is checked against it